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Abstract
Background. Quality of life (QOL) assessment in
patients on chronic haemodialysis (HD) or peritoneal
dialysis (PD) has only rarely been carried out with the
generic Euroqol-5D questionnaire.
Methods. All chronic HD and PD patients in the 19
centres of western Switzerland were requested to ﬁll
in the validated Euroqol-5D generic QOL question-
naire, assessing health status in ﬁve dimensions and on
a visual analogue scale, allowing computation of a
predicted QOL value, to be compared with the value
measured on the visual analogue scale.
Results. Of the 558 questionnaires distributed to
chronic HD patients, 455 were returned (response
rate 82%). Fifty of 64 PD patients (78%) returned the
questionnaire. The two groups were similar in age,
gender and duration of dialysis treatment. Mean QOL
was rated at 60±18% for HD and 61±19% for PD,
for a mean predicted QOL value of 62±30 and
58±32% respectively. Results of the ﬁve dimensions
were similar in both groups, except for a greater
restriction in usual activities for PD patients
(P¼ 0.007). The highest scores were recorded for self-
care, with 71% HD and 74% PD patients reporting no
limitation, and the lowest scores for usual activities,
with 14% HD and 23% PD patients reporting severe
limitation. Experiencing pain/discomfort (for HD and
PD) or anxiety/depression (for PD) had the highest
impact on QOL.
Conclusions. QOL was equally diminished in HD and
PD patients. The questionnaire was well accepted and
performed well. Improvement could be achievable in
both groups if pain/discomfort and anxiety/depression
could be more effectively treated.
Keywords: chronic renal failure; haemodialysis;
peritoneal dialysis; quality of life
Introduction
Chronic dialysis imposes a considerable burden on
patients [1] and families. Handicaps linked with co-
morbidities may worsen the situation. While previous
interest focused mostly on medical and technical
aspects of dialysis care, psychosocial aspects are now
increasingly explored, among them quality of life
(QOL) and satisfaction with care.
Many different generic and disease-speciﬁc ques-
tionnaires or interview techniques have been used for
assessing the QOL of patients with advanced kidney
disease [2]. Overall, studies have shown that global
QOL is severely impaired. Results were not always
consistent, because they were used at different stages of
the disease and in different settings. Comparisons
of QOL between haemodialysis (HD) and peritoneal
dialysis (PD) have also been performed at different
stages of the disease and in different settings. Results
were not always consistent in the ﬁrst place because
many different instruments were used: the generic
SF-36 questionnaire [3–7], the quality index score
developed by Spitzer [8], the generic EORTC-30
questionnaire [9], or speciﬁc instruments such as the
KDQOL-SF [6], or the CHOICE instrument [7].
All these instruments give multidimensional results,
have few dimensions in common and do not allow
comparison between them, nor a simple interpretation,
or a linkage with economic assessments.
So far, only two studies used the EuroQol-5D (EQ-
5D) generic questionnaire. One of them compared it
with the SF-36 [3] and the other used it along with
two other patient preference measurement tools, the
time trade-off and the standard gamble [10]. Despite
its infrequent use, the EQ-5D instrument has many
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advantages: it is very easy to use, has been translated
and validated in many languages, and its ﬁve questions
and visual analogue scale impose a minimal burden on
patients. In addition, it allows comparisons of QOL as
measured in individual patients with predicted values
derived from a sample general population, thus
confronting two different perspectives for the same
health states. Finally, the global score is a numeric
ﬁgure that can be used as a utility measure and
incorporated into economic evaluations. The primary
aims of this study were to assess predicted and
measured QOL values, and performance of the EQ-
5D instrument in chronic HD and PD patients in the
19 dialysis centres of western Switzerland.
Subjects and methods
Western Switzerland has a population of 1.8 million
inhabitants. The prevalence of dialysis treatment for end-
stage renal failure (ESRF) is 329–476/million. Nineteen
dialysis units (16 in the French-speaking area and three in the
German-speaking area) and nine PD centres, treat patients
with ESRF. Four units are privately owned, 15 are in the
public sector and two belong to tertiary care hospitals.
Eligible subjects were all dialysis patients treated in these
centres, as part of a study assessing quality of care in chronic
dialysis. Each patient was asked to complete the EQ-5D
generic QOL questionnaire. The EQ-5D was developed by
the international EuroQol group as a standardized generic
measure for description of health status [11]. This ques-
tionnaire is self-administered and composed of ﬁve items
addressing: mobility (problem in walking about), self-care
(problem with washing or dressing self), usual activities
(problem with performing usual activities), pain/discomfort
and anxiety/depression. Each item offers three response
categories including ‘no problem’, ‘some problems’ and
‘extreme problems’. In addition, the EQ-5D asks the patient
whether his/her health status has improved, has been stable
or has deteriorated over the last 12 months. Finally, each
patient is requested to evaluate his/her own overall health
on a visual analogue scale (EQ-VAS, or thermometer scale)
ranging from 0 (worst imaginable health state) to 100 (best
imaginable health state), leading to a ‘measured’ QOL score.
The combination of the three different levels of responses
recorded for each of the ﬁve items deﬁnes 243 possible health
states (35 possible combinations). Administration of the EQ-
5D to a sample of the general population allowed deﬁning a
value for each of these health states (health utility). These
values are provided with the instrument [12] and are used as a
weight for computing a ‘predicted’ QOL value, reﬂecting the
preference of the general population for these health states.
Measured scores on the visual analogue scale can then be
compared with the predicted scores. At the beginning of
the questionnaire, data about age, gender and duration of
dialysis treatment were requested, but the patient was not
obliged to provide his/her name, although space was left to
do so.
Questionnaires were distributed by the nursing staff and
the patients were asked to respond to the questions at
home and return the questionnaire to the dialysis centre, if
preferred anonymously, by dropping them into a drop box.
When patients had trouble reading, writing or understanding
the questionnaires, a dedicated nurse could provide assis-
tance. No recall procedure was carried out to increase the
response rate.
Results were analysed by dialysis treatment modality and
by centre. Analysis was repeated after restricting HD data to
the centres that also offered PD. Further analysis compared
the results by centre size (number of patients <25 or not), by
response rate (<90% or not), by teaching status and by type
of ﬁnancing (public vs private). Categorical variables were
compared with the 2 test and continuous variables with
Mann–Whitney U-tests or Student’s t-tests, as appropriate.
The relationship between the ﬁve items and the measured
QOL was assessed by linear regression, as were the relation-
ships with age, duration of treatment and health state over
the prior 12 months.
Quality performance of the questionnaire was assessed
as response rate to the different items and to the scale, and
distribution of responses over the different responses
categories.
Differences between measured and predicted QOL were
computed for each patient and means were computed for
each dialysis modality and centre. Differences in QOL and
differences between measured and predicted QOL by
evolution of health state were compared with a two-way
ANOVA. Statistical signiﬁcance was assumed for P values
<0.05.
Results
Centres treated a median of 24 HD patients (range
6–68), and were equipped with a median of 10 dialysis
beds (range 3–26, total 190). In the nine units
performing PD, a median of six PD patients (1–20,
total 64) were treated per centre.
Of the 558 questionnaires distributed to chronic HD
patients, 455 were returned (response rate 82%). The
centre-speciﬁc response rate ranged from 55.6 to 100%,
with a median of 92.9%. For PD patients, 50 of the 64
questionnaires were returned (response rate 78%). The
centre-speciﬁc response rate ranged from 50 to 100%,
with a median of 90%. Responders used the help of
dialysis nurses to complete the questionnaire only in a
few cases. Almost all patients (98%) were Caucasians.
HD and PD patients were not statistically different in
age (64±15 vs 60±17 years), gender (male gender 63
vs 55%) and duration of dialysis treatment (4.0±4.5
vs 3.2±4.9 years). Only 7.5% of HD and 8% of
PD patients had started dialysis in the year of the
study, and their health status assessment was not
different from the other patients. Responders were
also similar to the whole dialysis population treated in
the different dialysis centres, and no differences were
observed between the different centres. The corre-
sponding values when analysis was repeated by centre
size (> or <25 patients), response rate (> or <90%),
teaching status (teaching or not) and type of ﬁnancing
(public or private) are displayed in Table 1. Only three
statistically signiﬁcant differences were observed, for
which no obvious explanation exists: centres offering
both HD and PD had more male patients; PD centres
with high response rates were younger; and PD patients
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in teaching hospitals had been on dialysis for a longer
time.
Response rates to the ﬁve dimensions of the
questionnaire were very high, and responses were
distributed over all response categories. Detailed
distribution is displayed in Table 2. These results were
similar in the two groups, except for a greater
restriction in usual activities reported by PD patients
(P¼ 0.007, compared with HD patients). The highest
QOL scores were recorded for the dimension assessing
limitations in self-care, with >70% of both HD and PD
patients reporting no limitation, and the lowest scores
were recorded for limitation in usual activities, with
14% HD and 23% PD patients reporting severe
limitations (Table 2).
Mean predicted and measured QOL values were
similar in both dialysis groups and not different
between centres. However, individual correlation
between predicted and measured QOL values was low
(r¼ 0.197). The distribution of the recorded difference
is provided in Table 3. There was no association
between the direction or the magnitude of this
Table 1. Patient’s characteristics and response rate by centre
Number of
patients
Number of
respondents
Mean response
rate (%)
Male gender
(%)
Mean age
(years)
Mean duration of
dialysis (years)
HD centres (n¼ 19)
Total (all centres) 558 455
Median of centre means 24 19 92.9 67.4 64.4 3.8
Minimum mean 6 6 55.6 31.6 59.2 2.9
Maximum mean 68 56 100.0 83.9 69.9 6.4
HDþPD centre, n¼ 9 359 285 81.4 67.3a 64.9 4.4
HD only centre, n¼ 10 199 170 86.9 56.1 62.6 3.4
Large centre (>25 patients), n¼ 8 369 296 81.8 64.6 64.1 4.4
Small centre (<25 patients), n¼ 11 189 159 86.1 60.2 63.7 3.4
High response rate (>90%), n¼ 9 189 184 97.0b 59.4 63.4 4.2
Low response rate (<90%), n¼ 10 369 271 72.9 67.6 64.7 3.8
Teaching hospital, n¼ 2 127 99 77.6 68.4 63.2 5.4
Non-teaching hospital, n¼ 17 431 356 85.1 61.6 64.2 3.7
Public, n¼ 15 460 372 83.5 63.8 64.3 4.3
Private, n¼ 4 98 83 87.4 59.8 62.3 2.6
PD centres (n¼ 9)
Total (all centres) 64 50
Median of centre means 6 4 90.0 50.0 57.0 1.9
Minimum 1 1 50.0 0.0 21.0 1.3
Maximum 20 18 100.0 100.0 72.9 5.0
High response rate (>90%), n¼ 5 30 28 98.0b 46.4 55.6a 3.6
Low response rate (<90%), n¼ 4 34 22 60.4 68.2 67.1 2.5
Teaching hospital, n¼ 2 30 23 70.0 52.2 54.4 4.5a
Non-teaching hospital, n¼ 7 34 27 84.5 59.3 64.6 1.7
aP<0.05.
bP<0.001.
Table 2. Distribution of responses to EQ-5D, by type of dialysis
HD PD
(n,%) 1 (%) 2 (%) 3 (%) (n,%) 1 (%) 2 (%) 3 (%) P value
Euroqol dimensiona
Mobility (452, 99) 50 49 1 (50, 100) 42 56 2 0.295
Self-care (451, 99) 71 24 5 (50, 100) 74 16 10 0.246
Usual activity (443, 97) 36 50 14 (49, 98) 14 63 23 0.007
Pain/discomfort (439, 96) 30 64 6 (49, 98) 39 53 8 0.351
Anxiety/depression (442, 97) 52 42 6 (50, 100) 48 46 6 0.873
Health status evolutionb (445, 97) 34 51 15 (49, 98) 31 55 14 0.873
Predicted QOL valuec
(Mean±SD) (419, 92) 62.1±29.9 (49, 98) 58.1±32.3 0.378
Measured QOL valued (409, 90) 60.4±18.0 (46, 92) 61.2±18.9 0.787
(Mean±SD)
a 1¼ no problem, 2¼ some problem, 3¼ extreme problem.
bOver the last 12 months: 1¼ improved, 2¼ same, 3¼deteriorated.
cAs computed from the ﬁve dimensions.
dAs measured on the visual analogue scale.
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difference and age, gender, duration of dialysis treat-
ment or evolution of heath state over the last 12
months. However, for the different health states associ-
ated with no or little limitation in the ﬁve dimensions,
measured scores from our patients tended to be lower
than those predicted as derived from the general
population, while the contrary was true for health
states associated with moderate or severe limitations.
Measured QOL was not inﬂuenced by age, gender
duration of dialysis treatment, but was statistically
signiﬁcantly associated with the evolution of health
state over the previous 12 months (Table 4). Health
status over the prior 12 months was rated as stable in
approximately half of the patients and improved in
about a third. This ﬁnding was consistent for both HD
and PD patients.
The ﬁve items determining the predicted QOL
explained 33% of the variance observed in measured
QOL in HD patients, and 54.4% in PD patients. The
details of these results are displayed in Table 4. Four
out of ﬁve items were statistically signiﬁcant for HD
patients, and only two out of ﬁve for PD patients.
Pain/discomfort and anxiety/depression were asso-
ciated with very high regression coefﬁcients, although
the 95% conﬁdence interval was wide, indicating
substantial individual variations. However, these
results mean that, for example in PD patients, moving
from the stage of ‘no problem’ with pain/discomfort or
anxiety/depression to the stage of ‘some problem’
would be associated on average with a 10% decrease
in QOL, whereas the same move in HD patients would
on average decrease QOL by 6.8% for pain/discomfort,
but only by 3.5% for anxiety/depression.
Altogether, there was no statistically signiﬁcant
difference in response distribution between the 19
different HD centres or the nine PD centres, nor
when analysis was restricted to HD centres offering PD.
When analysis was repeated by centre size, response
rate, teaching status or type of ﬁnancing, only two
statistically signiﬁcant differences were observed: HD
patients in centres with low response rate reported more
pain/discomfort than HD patients in centres with high
response rates (P¼ 0.007); and HD patients in larger
centres reported more anxiety/discomfort than HD
patients in smaller centres (P¼ 0.032).
Discussion
This study showed that the generic QOL instrument
EQ-5D applied to chronic dialysis was well-accepted,
easy to use and responsive for both HD and PD
Table 4. Importance of the self-rated handicap in the ﬁve EQ-5D dimensions and of the evolution of health state over the last 12 months
on the QOL measured on the thermometer scale
HD PD
Value 95% Conﬁdence interval P value Value 95% Conﬁdence interval P value
aChange of mean QOL as a consequence of a change in Euroqol dimensions (1)
Dimension
Mobility 5.32 9.08 1.56 0.006 8.87 18.78 1.04 0.078
Self-care 3.44 6.98 0.10 0.056 1.27 9.05 6.51 0.743
Usual activity 5.94 8.91 2.97 <0.001 4.42 14.29 5.45 0.371
Pain/discomfort 6.75 9.77 3.72 <0.001 10.35 17.55 3.16 0.006
Anxiety/depression 3.51 6.11 0.92 0.008 10.39 17.67 3.11 0.006
Constant 101.02 94.75 107.28 <0.001 120.71 101.80 139.62 <0.001
R square 0.33 0.54
bMean QOL value by health state evolution over the last 12 months (2)
Health state
Improved 68.36 65.59 71.12 <0.001 71.86 64.58 79.14 <0.001
Stable 59.40 57.02 61.78 60.70 53.87 67.54
Deteriorated 47.69 43.47 51.91 34.00 15.17 52.83
Average 60.68 58.91 62.46 61.20 55.59 66.80
a Linear regression analysis: these results mean that a change from no problem to some problem with pain or discomfort would result in an
average 6.75% decrease in QOL for HD patients and an average 10.35% decrease in PD patients.
b Comparison of means by two-way ANOVA.
Table 3. Stratiﬁcation of the magnitude of differences between measured and predicted QOL values
Difference (points, scale 0–100) HD (%) (n¼ 383) PD (%) (n¼ 45) P value
>30 33 8.7 1 2.2
–21 to 30 46 12.2 4 8.9
–11 to 20 72 19.0 7 15.6
–10 to þ10 142 37.6 20 44.4 0.197
þ11 to þ20 23 6.1 3 6.7
þ21 to þ30 12 3.2 0 0.0
>þ30 50 13.2 10 22.2
Quality of life on chronic dialysis 1597
patients. QOL was substantially diminished in both
dialysis modalities, to a degree similar to that described
in prior studies [3,8,10]. Patients’ characteristics, such
as gender, age and duration of treatment had no impact
on these results. On the other hand, health status
change over the last 12 months explained 14 and 29%
of the variation in measured QOL for HD and PD
patients, respectively. There was a 10 and a 16%
decrease in QOL for HD and PD patients for a decrease
of one level in the health status over the prior 12
months. Centres’ characteristics such as size, response
rate, teaching status or type of funding were not related
to the results either in HD or PD patients.
The EQ-5D instrument measures health states along
ﬁve components reﬂecting physical, functional and
mental dimensions. Altogether, these ﬁve dimensions
explained a third and half of the observed variance in
QOL in HD and PD patients, respectively. Four of
these ﬁve dimensions were statistically signiﬁcant in
HD patients, and two of them in PD patients.
Interestingly, the dimensions associated with the
highest variation in QOL dealt with pain/discomfort
and anxiety/depression in both treatment modalities.
The prevalence of depression in our population of dial-
ysis patients was similar to the one described in prior
studies [1]. Although substantial individual variation
exist, as reﬂected by the wide 95% conﬁdence interval,
this ﬁnding is of particular interest and should attract
the attention of physicians because a speciﬁc treatment
is available. If successful, it would, on average, improve
QOL of these patients by 10–20%. This ﬁnding might
also explain why a study using the index score of Spitzer
[8] found that variance in responses was not explained
by case-mix variations only, which usually do not
include these variables. Thus, pain/discomfort and
anxiety/depression might deserve special attention,
because they are not always part of routine clinical
assessment.
PD is often presented as the easier and less
cumbersome dialysis modality, but is used for a
minority of patients. Even if the majority of our PD
patients performed automated PD, our results showed
that they reported a severe impairment in their usual
activities, which was greater than the one described by
HD patients. This surprising factor should be kept in
mind when information about dialysis modalities is
presented to patients with ESRF.
Another interesting ﬁnding was that no major
difference was recorded between the different dialysis
centres, in measured or predicted QOL, or even in the
differences between these two measures. This result is
not consistent with the ﬁndings by Mozes et al. [8], who
noted differences between dialysis centres, which were
not explained by differences in case-mix only. The small
size of our centres might explain these discrepant
results.
Although mean measured and predicted values were
similar for the whole population, individual correlation
between them was low (r¼ 0.197). This ﬁnding has
already been described when the EQ-5D was used in
other settings, such as chronic disorders (rheumatoid
arthritis, osteoarthritis of the knee) or intensive care
stays, or acute conditions such as AIDS. Several
explanations have been proposed: ﬁrst, different
raters assign different values to the same health state,
and consequently have different preferences for these
health states [13]; secondly, the predicted values are
derived from studies on the general population,
whereas the values measured on ‘thermometer’ scale
reﬂect the opinion of the patient. If they suffer from
chronic diseases, they are likely to alter their expecta-
tions and goals to cope with their limitations [14]. This
might explain why results on patients with chronic
diseases are consistent between them and not with those
observed on survivors of intensive care hospitalization.
Finally, the EQ-5D dimensions are recorded on a three-
point scale, which might force responses to the mid-
range category, as few patients endorse the ‘severe’
value, and some limitation is often present, which
diverts the answer away from the ‘no limitation’ value
[15]. A comparison of the EQ-5D ‘thermometer’ scale
results with those obtained on a ﬁve-point rating scale
showed results consistent with this hypothesis [16].
On the other hand, such a limitation of the EQ-5D
instrument can be viewed as an advantage in itself, as it
allows deriving preferences of both the patients and the
general population at the same time, and thus offers the
two most useful perspectives to incorporate into other
studies assessing the impact of diagnostic or therapeutic
procedures, such as economic analysis for example.
Our study has also limitations. First, its cross-
sectional design precludes comparison with QOL
before dialysis, which has been shown to have an
important impact [3–5]. Secondly, as it was designed to
be anonymous, no systematic link could be made with a
case-mix variable or with adequacy of dialysis [17],
which was found to have an impact on physical and
emotional dimensions in a study using the SF-36
questionnaire or on satisfaction with care [18].
Thirdly, any comparison between HD and PD should
be made with caution, because we did not exclude
therapy selection, or differences in QOL before dialysis
[3]. Therefore, our ﬁndings of a similar decrease in QOL
within the two groups should be put in perspective with
the ﬁndings of other studies using the SF-36 ques-
tionnaire. Merkus et al. showed a favourable effect
on physical QOL over time in HD patients, as com-
pared with PD patients [4], whereas Diaz-Buxo et al.
described no difference in HD patients in this dimen-
sion, but a higher score for mental processes in PD
patients, after adjustment for laboratory tests results
[5].
Further studies should assess how the EQ-5D
compares with other generic or disease-speciﬁc instru-
ments such as the SF-36 or the KD-QOL [6], or be
used as a predictor of poor outcomes [19], mortality
and hospitalization [20], as was shown for the SF-36
questionnaire.
In conclusion, the EQ-5D appeared to be a promis-
ing surveillance instrument for HD and PD patients. It
showed that ESRF patients experience low levels of
QOL with both dialysis modalities, but that some
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characteristics could be better targeted to improve their
QOL. In addition, the very high response rate observed
in this study was encouraging: it indicated that patients
were willing to participate in this kind of survey. As a
consequence, EQ-5D could be used more frequently by
other dialysis centres in our country or abroad, as it is
simpler to administer compared with the more widely
used SF-36 questionnaire, and can be linked with other
kinds of studies, including economic analyses.
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